Company intelligence / Profile preview

Centaflow

Ownership: Private
Development stage: Other

Overview

Centaflow has developed a non-invasive clinical system that uses advanced acoustic sensing and artificial intelligence to detect abnormal blood flow in the placenta. The system aims to enable earlier diagnosis of placental dysfunction, improving outcomes for pregnant women and fetuses. The technology is based on extensive research involving thousands of recordings from pregnant women and leverages Danish expertise in acoustics. It is designed to be used as part of standard prenatal care by healthcare professionals.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Collaborations with universities

Beyond the preview

Go deeper on Centaflow.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centaflow.

Explore the full profile